European Commission Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Approval Based on Data From the Phase 1/2 ‘205 Study THOUSAND OAKS, Calif., Aug. 29, 2018 – Amgen (NASDAQ:AMGN) today announced that ...